Liraglutide vs Semaglutide: Two Generations of GLP-1

Published May 25, 2026Updated May 27, 2026Last reviewed May 25, 2026

For the broader cluster context, see the semaglutide vs Ozempic and Wegovy comparison hub.

Author: HealthRX Editorial Team Medically reviewed by: Dr. Mark Halpern, MD (Internal Medicine, Obesity Medicine) Last clinical review: May 2026

Compounded semaglutide is not FDA-approved. This article is patient education and does not replace consultation with a licensed clinician.

Last October, a 47-year-old accountant named Rachel in Portland, Oregon, sat across from her obesity medicine doctor holding two printouts she'd pulled from Reddit. One thread said liraglutide was "basically the flip phone version" of semaglutide. The other swore liraglutide was gentler and therefore better for long-term adherence. Her doctor, who'd prescribed both molecules to hundreds of patients, told her something she didn't expect: "The right answer depends on about six things, and the molecule is maybe number four on the list." Rachel ended up on compounded semaglutide at 0.5 mg weekly, titrated over twelve weeks. She lost 31 pounds in seven months. But her story could have gone differently, and the reasons why are what this article is actually about.

This guide sits inside the broader Compounded Semaglutide vs Ozempic and Wegovy cluster, which is part of the compounded semaglutide pillar guide.

The Molecules, Stripped Down

Both liraglutide and semaglutide are GLP-1 receptor agonists developed by Novo Nordisk. They mimic the incretin hormone GLP-1, which tells the pancreas to release insulin after a meal, slows gastric emptying, and acts on appetite centers in the brain. Same mechanism class. Same manufacturer. That is roughly where the similarity ends.

Liraglutide is a once-daily injection. It is the active ingredient in Victoza (approved for type 2 diabetes) and Saxenda (approved for chronic weight management). Its half-life is about 13 hours, which is why you inject it every day.

Semaglutide is a once-weekly injection. Its molecular structure includes a fatty acid side chain and amino acid modifications that let it bind more tightly to albumin in the blood, dragging its half-life out to roughly seven days. It's the active molecule in Ozempic (type 2 diabetes indication) and Wegovy (chronic weight management indication). Those are the same molecule at different dose ceilings with different labels.

Compounded semaglutide uses the same active ingredient as Ozempic and Wegovy. It is prepared by a licensed compounding pharmacy under a clinician prescription. It is not FDA-approved. The published evidence base for the molecule comes from trials conducted with the branded products; compounded preparations have not been independently tested in randomized trials at the same scale.

Think of it like this: liraglutide was the proof of concept that a GLP-1 agonist could treat obesity. Semaglutide was the refinement, a longer-acting molecule with a more potent effect at the receptor level and a dosing schedule most people actually stick with.

What the Head-to-Head Data Actually Shows

When clinicians compare liraglutide vs semaglutide, they aren't guessing. There is real trial data.

For glycemic control, SUSTAIN-10 put semaglutide 1.0 mg weekly against liraglutide 1.2 mg daily in patients with type 2 diabetes. Semaglutide won on A1c reduction and weight loss. That trial was designed for the diabetes indication, but the weight loss differential was hard to ignore.

For weight management, we don't have a perfect head-to-head at the obesity doses. What we have is cross-trial comparison: the SCALE program tested liraglutide 3.0 mg daily, and the STEP program tested semaglutide 2.4 mg weekly. STEP-8 specifically compared semaglutide to liraglutide and found significantly greater weight loss with semaglutide. The mean weight loss with semaglutide 2.4 mg in STEP-1 was 14.9 percent from baseline over 68 weeks. The SCALE trials for liraglutide generally reported around 8 percent. That is a meaningful gap.

Here's the thing, though. Averages describe populations, not individuals. Some people respond beautifully to liraglutide and poorly to semaglutide. Some people cannot tolerate the GI side effects of semaglutide at any dose but do fine on liraglutide. The trial means are useful for comparison, but your prescriber is looking at you, not a forest plot.

Why Some Clinicians Still Start with Liraglutide

Given the weight loss numbers, you might wonder why anyone bothers with the older molecule. A few reasons.

Tolerability. Liraglutide's shorter half-life means that if a patient has a bad reaction, it clears the system faster. For patients with a history of severe GI sensitivity, some obesity medicine physicians prefer to start with liraglutide, confirm tolerable response, and then consider transitioning to weekly semaglutide. It's a slower road, but it keeps patients in treatment rather than dropping out after one miserable week.

Prior authorization logistics. Insurance coverage for branded GLP-1s is, to put it politely, a mess. Sometimes a patient can get one brand covered but not the other. The clinical choice becomes partly an administrative one, which is frustrating for everyone involved but is the reality of practicing medicine in 2026.

The cardiovascular story. LEADER established the cardiovascular safety profile for liraglutide in type 2 diabetes. SUSTAIN-6 did the same for semaglutide. And then SELECT, completed in 2023, went further: it showed a 20 percent relative reduction in major adverse cardiovascular events with semaglutide 2.4 mg in patients with established cardiovascular disease and overweight or obesity without diabetes. That finding pushed semaglutide ahead in cardiovascular risk conversations, but it doesn't erase liraglutide's role entirely. A patient already stable on liraglutide with good cardiovascular markers and consistent weight loss may not need to switch.

My honest take: for most patients starting GLP-1 therapy for weight management in 2026, semaglutide is the stronger choice on efficacy and convenience. But "for most patients" does real work in that sentence. The exceptions matter clinically.

Where Compounded Semaglutide Fits

Access is the elephant in every GLP-1 conversation. Branded Wegovy at list price runs north of $1,300 per month without insurance. Ozempic is in a similar range. Many patients cannot get insurance coverage, or they get it and then face supply disruptions.

Compounded semaglutide operates under a different cost structure. It is prepared by licensed 503A or 503B compounding pharmacies under patient-specific clinician prescriptions. The active ingredient is the same molecule. The regulatory pathway is not the same. Compounded preparations are not FDA-approved, and the manufacturing oversight framework differs from that of branded products.

This matters practically in a few ways. Compounded programs can adjust dosing with more granularity than the pre-filled pen products allow. A patient who needs 1.7 mg (a dose that doesn't exist in a branded pen) can get exactly that from a compounding pharmacy. That flexibility is not trivial when you're managing GI side effects or trying to find the minimum effective dose.

The catch is that not all compounding pharmacies are created equal. The clinical infrastructure around the prescription, meaning the prescriber relationship, the follow-up cadence, the willingness to adjust dose when things aren't working, matters as much as the molecule itself. A well-run clinical program with compounded semaglutide will outperform a sloppy program with a branded pen. The reverse is also true.

The Lifestyle Multiplier

One finding from the STEP program deserves more attention than it usually gets. STEP-1 tested semaglutide 2.4 mg weekly with standard lifestyle counseling and reported mean weight loss of 14.9 percent. STEP-3 paired the same dose with an intensive behavioral intervention (a structured low-calorie diet for the first eight weeks, followed by regular dietitian contact) and produced higher mean weight loss.

The implication is straightforward: the medication reduces appetite and slows gastric emptying, which creates a window of opportunity. What a patient does inside that window, the food choices, the activity, the behavioral patterns, determines how much benefit they extract from therapy. When total calorie intake drops significantly, every meal carries more nutritional weight. A 1,400-calorie day with 90 grams of protein and vegetables looks very different from a 1,400-calorie day of processed snacks, even though the scale might not distinguish between them in the short term.

And then there's STEP-4, which documented what happens when the medication stops. Patients who switched from active semaglutide to placebo at week 20 experienced partial weight regain over the subsequent 48 weeks. This is not a failure of willpower. It is the chronic biology of weight regulation reasserting itself, the same way blood pressure rises again when you stop an antihypertensive. The implication is that for many patients, pharmacotherapy for obesity is a long-term proposition, not a 12-week fix.

Misconceptions That Keep Circulating

"Compounded semaglutide is the same thing as Wegovy." Same active ingredient, yes. Same regulatory status, no. Compounding pharmacies operate under a different framework with different oversight. This distinction matters and should be part of the conversation with your prescriber.

"If it doesn't make you nauseous, it's not working." Trial data from STEP-1 and STEP-3 don't support this. Patients with mild GI symptoms and patients with pronounced GI symptoms both achieved meaningful weight loss. Nausea is a common side effect, not a biomarker of efficacy.

"Liraglutide is basically worthless now that semaglutide exists." Overstated. Semaglutide is more potent for most endpoints tested. That doesn't mean liraglutide has zero clinical utility. Some patients tolerate it better. Some have insurance that covers Saxenda but not Wegovy. Clinical decisions are more nuanced than "newer equals better in all cases."

"You can stop after you hit your goal weight." STEP-4 says otherwise. The chronic biology of obesity doesn't resolve because you reached a number on the scale. Discontinuation should be a planned conversation with your prescriber, not a unilateral decision.

Adjacent Reading

Where This Fits

This article is part of the Compounded Semaglutide vs Ozempic and Wegovy cluster. For a broader treatment of the molecule, the regulatory pathway, the 503A and 503B compounding framework, and the clinical evidence base, the compounded semaglutide pillar guide is the primary reference on this site.

Frequently Asked Questions

Is compounded semaglutide the same as Ozempic or Wegovy?

Compounded semaglutide uses the same active ingredient, semaglutide. It is prepared by a licensed compounding pharmacy under a clinician prescription and is not FDA-approved. Wegovy and Ozempic are FDA-approved branded products manufactured by Novo Nordisk. Same molecule, different regulatory and manufacturing pathways.

What evidence applies across these forms?

The clinical trial evidence for semaglutide as a molecule comes from the SUSTAIN, STEP, and SELECT programs, all conducted with the branded products. Compounded preparations have not undergone equivalent randomized controlled trials.

Can patients switch between compounded and branded semaglutide?

Yes, but it is a clinical decision that depends on current dose, tolerability, and access. Switching is supervised by the prescriber and typically involves confirming dose equivalence and monitoring for any changes in response.

Is liraglutide still worth considering if semaglutide is available?

For most patients, semaglutide offers greater efficacy and a more convenient dosing schedule. But liraglutide remains a reasonable option in specific scenarios: patients who tolerate it better, patients with insurance that covers Saxenda but not Wegovy, or patients whose clinicians prefer a daily dosing option for clinical reasons.

How long do patients typically stay on GLP-1 therapy?

Current evidence, particularly from STEP-4, suggests that weight management with GLP-1 agonists is often a long-term treatment. Discontinuation tends to result in partial weight regain. The duration of therapy is an ongoing clinical conversation, not a predetermined endpoint.

Do side effects predict how much weight I'll lose?

No. STEP-1 and STEP-3 data show that patients across the spectrum of GI side effect severity achieved clinically meaningful weight loss. More nausea does not mean more weight loss.

Compliance and Authorship

This article references the STEP-1, STEP-3, STEP-4, STEP-8, SUSTAIN-6, SUSTAIN-10, SCALE, SELECT, and LEADER clinical trial programs where appropriate. It is intended as patient education and does not replace consultation with a licensed clinician.